Phenylpropanolamine
RESPIRATORY SYSTEM
Also known as: (+/-)-phenylpropanolamine, norephedrine, phenylpropanolamine HCl, phenylpropanolamine hydrochloride, phenylpropanolamine polistirex, propadrine
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Phenylpropanolamine is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 2000. DrugCentral lists 13 molecular targets, including SLC6A2, SLC6A3 and Adra2b. Recorded indications include Allergic conjunctivitis, Allergic rhinitis, Common cold and Cough.
- Approval status: ofm (first approved 2000 by the FDA).
- Molecular targets: SLC6A2, SLC6A3, Adra2b and ADRA2C (13 listed in DrugCentral).
- Indications: Allergic conjunctivitis, Allergic rhinitis, Common cold, Cough and Influenza-like symptoms and others.
- ATC code: R01BA01 (Sympathomimetics).
- Molecular formula: C9H13NO; molecular weight 151.21 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (12)
- Allergic conjunctivitis
- Allergic rhinitis
- Common cold
- Cough
- Influenza-like symptoms
- Nasal congestion
- Nasal discharge
- Rhinitis
- Seasonal allergic rhinitis
- Sinus headache
- Sneezing
- Vasomotor rhinitis
Off-label uses (1)
- Obesity
Contraindications (87)
- Acidosis
- Acute abdominal pain
- Acute erosive gastritis
- Acute hepatitis
- Acute nephropathy
- Acute pancreatitis
- Agoraphobia
- Alcohol intoxication
- Alcohol withdrawal delirium
- Alcoholism
- Anemia
- Anemia due to enzyme deficiency
- Angle-closure glaucoma
- Arterial thrombosis
- Arteriosclerotic vascular disease
- Asthenia
- Benign intracranial hypertension
- Benign prostatic hyperplasia
- Bladder outflow obstruction
- Bradycardia
- Breastfeeding (mother)
- Central nervous system depression
- Chronic heart failure
- Chronic idiopathic constipation
- Chronic obstructive lung disease
- Coma
- Conduction disorder of the heart
- Constipation
- Cor pulmonale
- Decreased respiratory function
- + 57 more
Mechanism & targets
Molecular targets (13)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Sodium-dependent noradrenaline transporter | SLC6A2 | unknown | Ki 7.82 |
| Sodium-dependent dopamine transporter | SLC6A3 | unknown | Ki 7.17 |
| Alpha-2B adrenergic receptor | Adra2b | unknown | Ki 6.58 |
| Alpha-2C adrenergic receptor | ADRA2C | unknown | Ki 6.58 |
| Alpha-2A adrenergic receptor | ADRA2A | unknown | Ki 6.56 |
| Alpha-2B adrenergic receptor | ADRA2B | unknown | Ki 6.40 |
| Muscarinic acetylcholine receptor M1 | CHRM1 | unknown | Ki 5.17 |
| 5-hydroxytryptamine receptor 7 | HTR7 | unknown | Ki 5.16 |
| Alpha-1D adrenergic receptor | Adra1d | unknown | Ki 5.07 |
| Alpha-1B adrenergic receptor | ADRA1B | unknown | Ki 5.02 |
| Alpha-1A adrenergic receptor | Adra1a | unknown | Ki 5.01 |
| Potassium voltage-gated channel subfamily H member 2 | KCNH2 | unknown | — |
| Alpha-1A adrenergic receptor | ADRA1A | agonist | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2000-09-29 | FDA | — | ALPHARMA US PHARMS |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
R01BA01 | RESPIRATORY SYSTEM › NASAL PREPARATIONS › NASAL DECONGESTANTS FOR SYSTEMIC USE › Sympathomimetics |
R01BA51 | RESPIRATORY SYSTEM › NASAL PREPARATIONS › NASAL DECONGESTANTS FOR SYSTEMIC USE › Sympathomimetics |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Toxicity to various agents | 75.2 |
| Sudden cardiac death | 42.2 |
| Maternal exposure before pregnancy | 41.2 |
Chemical structure
| Molecular formula | C9H13NO |
|---|---|
| Molecular weight | 151.21 g/mol |
| CAS number | 14838-15-4 |
| InChIKey | DLNKOYKMWOXYQA-UHFFFAOYSA-N |
| PubChem CID | 10297 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Phenylpropanolamine used for?
DrugCentral lists the following indications for Phenylpropanolamine: Allergic conjunctivitis, Allergic rhinitis, Common cold, Cough, Influenza-like symptoms, Nasal congestion, Nasal discharge and Rhinitis and others.
How does Phenylpropanolamine work?
Its molecular targets in DrugCentral include SLC6A2, SLC6A3, Adra2b and ADRA2C.
When was Phenylpropanolamine first approved?
Phenylpropanolamine was first approved by the FDA in 2000.
What is the chemical formula of Phenylpropanolamine?
Phenylpropanolamine has the molecular formula C9H13NO and a molecular weight of 151.21 g/mol.
Browse: all drugs starting with P · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2149 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1200695 — compound record and bioactivity
- PubChem CID 10297 — chemical identifiers
- DrugBank DB00397 — drug record
- FDA UNII 33RU150WUN — substance identity
- DailyMed: FDA labels for Phenylpropanolamine — current prescribing information (label search)
- UniProt P23975 (SLC6A2) — target protein
- UniProt Q01959 (SLC6A3) — target protein
- UniProt P18825 (ADRA2C) — target protein
- UniProt P08913 (ADRA2A) — target protein
- UniProt P18089 (ADRA2B) — target protein
- UniProt P11229 (CHRM1) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.